{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-018181","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.307775+00:00","generated_at":"2026-06-04T01:44:16.674967+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bionano Genomics raises $10M via registered direct offering of common stock and warrants at $1.145/share","bullets":["Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.","Gross proceeds ~$10M; net proceeds for working capital, R&D, debt repayment, and capex.","Expected closing on April 8, 2024; H.C. Wainwright acts as sole placement agent with 6% cash fee.","Offered under effective shelf registration statement (File No. 333-270459); warrants include beneficial ownership limitations of 4.99%/9.99%."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-018181","json":"https://secwatch.observer/filing/0001140361-24-018181.json","markdown":"https://secwatch.observer/filing/0001140361-24-018181.md","text":"https://secwatch.observer/filing/0001140361-24-018181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/0001140361-24-018181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/ef20026117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:44:16.674967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c429b8a45913bbc51fb26da504f155b72e8b326","claim":"Bionano Genomics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.0 million (effective 2024-04-04).","evidence_excerpt":"On April 4, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) an aggregate of 6,536,682 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 2,196,944 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 8,733,626 shares of Common Stock (the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/0001140361-24-018181-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $10.0 million"},{"label":"Effective","value":"2024-04-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}